Advertisement

February 20, 2014

Stryker Launches Trevo XP ProVue Retrieval System

February 21, 2014—Stryker Neurovascular (Kalamazoo, MI) announced the global launch of the Trevo XP ProVue retriever, which expands the company’s line of ProVue stent retrievers with additional size and shape options in the treatment of patients with acute ischemic stroke. The device, which provides full-length visibility, has been granted 510(k) clearance by the US Food and Drug Administration and is also available in international markets where it has been cleared for sale.

According to Stryker, the Trevo XP ProVue retriever is supported by robust clinical evidence from the TREVO and TREVO 2 clinical trials, which demonstrated high revascularization and a high rate of good clinical outcomes compared to the company’s earlier-generation Merci retriever. Additionally, physicians participating in the Trevo Retriever Registry, a multicenter, international data collection study, will be collecting real-world data on the Trevo XP ProVue retriever.

In the company’s press release, Ronald Budzik, MD, commented, “The Trevo XP ProVue retriever provides some of the best performance of the devices I’ve used over the years to treat acute ischemic stroke. The unique full-length visibility provides key information that we can use to successfully remove clots more efficiently. When combined with the Merci balloon guide catheter, I feel I have a system that is easy to use and provides the potential for consistently good results.” Dr. Budzik is Co-Director of the Riverside Comprehensive Stroke Center of OhioHealth at Riverside Methodist Hospital in Columbus, Ohio.

Joey D. English, MD, added, “The new Trevo XP ProVue Retriever is smooth and easy to use. It has excellent deliverability, and the visibility it provides allows me to confidently deploy the device in the best position to capture and remove the clot. I can visualize the clot and strut interaction during the case, and this provides valuable feedback for clot removal.” Dr. English is Director of Neurointerventional Services at California Pacific Medical Center in San Francisco, California.

Advertisement


February 21, 2014

BTG Announces 1-Year Data From VANISH-2

February 21, 2014

BTG Announces 1-Year Data From VANISH-2